Oral Peptide Administration Workshop Highlights Advances in Clinical Programs, Permeation Enhancers, and Preclinical Model Limitations
Background
Delivering therapeutic peptides orally presents significant challenges due to their susceptibility to enzymatic degradation in the gastrointestinal tract, poor permeability across the intestinal barrier, and low bioavailability. Current standard-of-care often relies on injectable formulations, which can impact patient adherence and quality of life. Overcoming these hurdles is crucial for expanding the accessibility and utility of peptide-based drugs, making oral peptide administration a critical area of research and development in drug delivery science.
Study Design
The Controlled Release Society (CRS) convened its fourth workshop on oral peptide administration on July 14, 2025, in Philadelphia, United States. Titled 'Recent advances in oral peptide delivery: from molecule to market,' the event was co-sponsored by major pharmaceutical companies including Novo Nordisk, Johnson and Johnson, and Merck. The workshop featured nine talks and two roundtable sessions, aiming to provide updates on current clinical oral peptide programs, discuss mechanistic progress on permeation enhancers, and evaluate the limitations of preclinical bioassays and animal models in this field.
Results
The workshop underscored the sustained interest in oral peptide administration, evidenced by the release of several oral peptide products into the market since previous iterations of the event. Discussions highlighted significant progress in understanding the mechanisms of action for permeation enhancers, which are crucial for improving the bioavailability of orally delivered peptides. A key focus was on the current landscape of clinical oral peptide programmes, showcasing the translational efforts from research to market.
Participants also critically evaluated the inherent limitations of preclinical bioassays and animal models, emphasizing the need for more predictive and robust systems to accelerate the development of new oral peptide therapies. The event served as a platform for sharing insights into both the technical advancements and the commercial challenges involved in bringing these complex drug products to patients, reflecting a dynamic and evolving research landscape.
Key Findings
- Several oral peptide products have successfully reached the market, demonstrating feasibility.
- Significant mechanistic progress in
permeation enhancersis improving oral peptide bioavailability. - Current
clinical oral peptide programmesare advancing, moving from research to market. - Limitations of
preclinical bioassaysand animal models require critical evaluation for better predictability. - Oral peptide administration remains a topic of intense technical and commercial interest.
Why It Matters
This workshop summary highlights the accelerating pace of innovation in oral peptide delivery, signaling a future where more peptide therapies could be available in convenient oral forms. For peptide users and clinicians, this means potentially fewer injections and improved adherence for chronic conditions currently managed by injectables. The focus on permeation enhancers and improved preclinical models suggests that the development pipeline for new oral peptides is becoming more robust. Understanding the current state and challenges in oral peptide administration is crucial for guiding future research and investment, potentially leading to novel co-formulations and delivery systems that overcome existing bioavailability barriers.
oral-peptide-delivery
drug-delivery
peptide-therapeutics
controlled-release
permeation-enhancers
preclinical-models